Fig. 9

Modulating BDNF in obese-prone and obese-resistant mice. Schematic representation of the protocol employed to modulate BDNF in obese-prone (OP) and obese-resistant (OR) mice (a). Body mass variation (b), percent fat mass as determined by PET-CT scan (c), and mean daily food intake (d) in the experimental models. In e–h, real-time PCR determination of the expression of transcripts encoding for IGFBP2 (e), NGFR (f), TNFα (g), and IL6 (h) in the median eminence of mice. In e–h, n = 4; *p < 0.05 vs. respective control. aBDNF treated with immunoneutralizing antibody against BDNF, BDNF brain-derived neurotrophic factor, IGFBP2 insulin-like growth factor-binding protein 2, IL6 interleukin-6, NGFR nerve growth factor receptor, Sal saline, TNFa tumor necrosis factor-alpha, wk week